ChitogenX (TSE:CHGX) has released an update.
ChitogenX, a clinical-stage regenerative medicine company, has reported a marginal Q1 2025 loss of $0.2 million, a notable improvement from the previous year, alongside positive EBITDA and reduced operational spending. The company is advancing towards commercial readiness, concentrating on securing capital and partnerships for their key programs in burn healing and skin repair. ChitogenX remains committed to reaching its corporate milestones with a strategic focus on non-dilutive and traditional financing.
For further insights into TSE:CHGX stock, check out TipRanks’ Stock Analysis page.
